Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.35 |
| ▸ | SLC9A3 | P48764 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492977 | 0.98 | BDKRB1 (0.36) | ACLYALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL492978 | 0.91 | ACLY (0.37) | ACLYALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL493513 | 0.89 | ALDH1A1 (0.35) | ACLYALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL493414 | 0.85 | BDKRB1 (0.41) | ALDH1A1SMN1; SMN2GAABDKRB1 | |
| SCHEMBL493311 | 0.83 | BDKRB1 (0.41) | BDKRB1 | |
| SCHEMBL492975 | 0.80 | CACNA2D1 (0.37) | ALDH1A1TDP1SMN1; SMN2MEN1POLB | |
| SCHEMBL3412474 | 0.79 | L3MBTL1 (0.38) | ALDH1A1TDP1SMN1; SMN2MEN1POLB | |
| SCHEMBL492596 | 0.79 | ALDH1A1 (0.37) | ALDH1A1TDP1SMN1; SMN2MEN1POLB | |
| SCHEMBL493014 | 0.79 | LMNA (0.40) | ALDH1A1SMN1; SMN2MEN1KMT2ASLC9A3 | |
| SCHEMBL3406387 | 0.79 | ALDH1A1 (0.37) | ALDH1A1TDP1SMN1; SMN2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | ACLY 80/4885ALDH1A1 1349/4885TDP1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.